PLRX — Pliant Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.14
+$0.02 (+2.25%)
Pliant Therapeutics Inc (PLRX) is a biotechnology company listed on NASDAQ. It is led by Bernard Coulie M.B.A., M.D., Ph.D., based in 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, with about 171 employees. Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Net income was -$26.3M. PLRX currently screens at market cap $77.3M.
Use this PLRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PLRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PLRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Pliant Therapeutics Inc even when a live quote feed is slow.
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
PLRX Key Statistics
Market Cap
$77.35M
Volume
204,320
Previous Close
$1.14
Day Range
$1.13 – $1.16
EPS
-$3.47
Revenue
$0.00
Net Income
-$210.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
171
PLRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $1.58M | $9.69M | $7.57M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$210.30M | -$161.34M | -$123.32M | -$97.26M |
| EPS (Diluted) | -$3.47 | -$2.75 | -$2.94 | -$2.71 |
Total Assets
$396.95M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.19M
Operating Cash Flow
-$155.50M
Free Cash Flow
$0.00
Pliant Therapeutics Inc Company Information
- President, CEO & Director
- Bernard Coulie M.B.A., M.D., Ph.D.
- Headquarters
- 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Website
- pliantrx.com
- Phone
- 650 481 6770
- IPO / Founded
- 2020-06-03
- Sector
- Healthcare
- Industry
- Biotechnology